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Abstract The check-points that maintain stoichiometric syn-
thesis of muscle proteins were examined by misexpression of
slow troponin C (sTnC) in mouse C2 myotubes. The sTnC
mRNA was overexpressed in myotubes by transfecting these cells
with a plasmid construct containing the constitutive CMV
promoter-driven sTnC cDNA. An approximately four-fold
increase of sTnC mRNA level in the transfected cells was
observed. However, the increased mRNA level did not produce a
corresponding increase of the sTnC polypeptide level in
transfected cells. Only a modest 1.5-fold increase of the sTnC
polypeptide level in the transfected cells was observed. The
excess sTnC polypeptide in transfected cells was found in the
soluble form which was not complexed with other thin filament
proteins. The difference between the increase of sTnC mRNA
and the polypeptide levels in transfected cells was not due to
inefficient translation of the overexpressed sTnC mRNA.
Analyses of the stability of the sTnC polypeptide in the thin
filament and in the unassembled soluble forms showed that the
excess soluble sTnC polypeptide was degraded more rapidly
than the sTnC polypeptide of the thin filament. Analyses of
the mRNA and polypeptide levels of several thin filament
complements showed no effect of overexpression of the sTnC
mRNA. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Formation of the contractile apparatus in muscle cells re-
quires the activation of several genes and proper assembly of
their polypeptide products. During di¡erentiation of commit-
ted myoblasts to terminally di¡erentiated myotubes expres-
sions of various muscle speci¢c genes are coordinately acti-
vated [1,2]. Most of the contractile proteins are coded by
single copy genes [1], yet di¡erent amounts of these proteins
are produced from these genes to form the myo¢lament. For
instance, seven molecules of actin and one molecule of each of
the troponin subunits and tropomyosin (Tm) are required to
form the thin ¢lament [3].
Di¡erences in the rates of transcription among the genes for
contractile proteins may produce di¡erent amounts of mRNA
from these genes. Also di¡erences in mRNA stability, e⁄-
ciency of their translation and stability of polypeptides, all
contribute toward the ¢nal steady state level of polypeptides
[4,5]. How all of these levels of regulation are ¢ne tuned to
produce stoichiometric amounts of the di¡erent contractile
proteins to form the myo¢lament is not clear. Misexpression
of one component of the myo¢lament will disrupt the stoichi-
ometry. How this process might in£uence the assembly and
maintenance of the myo¢lament and a¡ect the synthesis of
other contractile proteins needs to be examined in detail.
Various methods may be used for misexpression of a poly-
peptide partner of the myo¢lament. One simple method is to
use antisense oligodeoxynucleotides to block the expression of
a speci¢c gene for one of the muscle proteins [6^11]. Another
approach is the transient overexpression of a speci¢c polypep-
tide of the myo¢lament by transfecting muscle cells with an
appropriate ectopic gene. We chose slow troponin C (sTnC)
as a model system to investigate the e¡ect of its misexpression
in muscle cells. Troponin C is the smallest subunit of the
troponin complex involved in regulating muscle contraction
by Ca2 [3,12]. Troponin C is a highly conserved Ca2 bind-
ing protein [12]. The two known isoforms of TnC (slow and
fast) are separate gene products [13,14]. The fast TnC occurs
exclusively in fast skeletal muscle, whereas the slow isoform is
present in both skeletal and cardiac muscle. However, in car-
diac muscle the slow isoform is the only isoform found in the
troponin complex [14^16]. Generally the TnC genes are not
expressed in non-muscle cells. The only known exceptions are
the presence of sTnC in human ¢broblasts and chicken liver
and brain cells [17,18]. The C2 myogenic cell line derived from
mouse skeletal muscle following di¡erentiation to myotubes
produces predominantly the slow TnC isoform as well as a
small amount of the fast isoform [13,14]. The expression pat-
tern of sTnC in C2 muscle cells is less complicated than other
muscle proteins which exhibit a more complex isoform expres-
sion pattern in muscle cells [19]. Therefore, misexpression of
the predominant isoform of TnC in these cells may be a good
model to study the check-points that control stoichiometric
production of contractile proteins.
In previous studies, misexpression of the sTnC gene was
achieved by blocking its expression by antisense oligodeoxy-
nucleotides. Although 50^70% inhibition of synthesis of these
polypeptides was achieved, very little e¡ect was seen on the
synthesis of other contractile proteins [6^8]. Detailed investi-
gation of how the myo¢lament is maintained under reduced
sTnC synthesis revealed that the stability of the sTnC poly-
peptide is increased to compensate for its reduced synthesis
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[8]. The studies reported here used overexpression of sTnC to
disrupt the stoichiometric synthesis of contractile proteins.
The results show that the proper myo¢lament assembly was
maintained by rapidly degrading the unassembled excess
sTnC.
2. Materials and methods
2.1. Construction of sTnC expression vector
A full length mouse sTnC cDNA clone was obtained from IMAGE
consortium (image 1139312). The entire cDNA insert was ampli¢ed
by PCR using the d(5P-ggatccGGGAGCAAGGATTTATGTG) and
5P-cctaggTTCGGATCCTTGGTGAGCT primers with recognition se-
quences of BamHI and AvrII restriction enzymes respectively (indi-
cated by lowercase letters). The PCR reaction was carried out in the
bu¡er containing 10 mM Tris^HCl, pH 9.0, 1.5 mM MgCl2, 50 mM
KCl, 0.1% Triton X-100, 200 WM dNTPs, 200 ng of each primer, 2
units of Taq polymerase, 20 ng of image sTnC cDNA clone as tem-
plate for 30 cycles [20]. Each cycle was at 94‡C for 15 s, 50‡C for 30 s
and 72‡C for 1 min and the ¢nal cycle was at 72‡C for 5 min. The
ampli¢ed product was puri¢ed by ion exchange chromatography us-
ing a PCR puri¢cation kit (Qiagen, Valencia, CA, USA) and digested
with AvrII and BamHI restriction enzymes. The digested product was
gel puri¢ed using a Qiagen kit. For constructing the sTnC expression
vector, this fragment was ligated to the 4.3 kb AvrII/BamHI fragment
of CMV-SPORT-L-gal plasmid (Gibco/BRL, Burlington, ON, Cana-
da).
2.2. Cell culture
Mouse skeletal muscle C2 myoblast cell line (ATCC CRL 1772)
was grown in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (Invitrogen, Burlington, ON,
Canada). Di¡erentiation of myoblasts to myotubes was induced by
transferring 60% con£uent cells to the serum free OPTIMEM (Invi-
trogen) for 24 h followed by addition of 2.5% horse serum containing
DMEM. Long multinucleated myotubes were formed after 3 days of
induction of di¡erentiation. The mRNA for contractile proteins ap-
peared within 12 h of induction [21].
2.3. Transfection of cells
Approximately 5U105 C2 cells grown on a six-well dish were trans-
fected with the appropriate plasmid DNA, after transfer to the OP-
TIMEM medium for di¡erentiation. 1^2 Wg of DNA was mixed with
10 Wg of lipofectamine (Invitrogen) in 400 Wl of OPTIMEM at 20‡C
for 30 min before being added to the cells. Cells were incubated with
the DNA/liposome mixture for 24 h, and then the medium was re-
moved, and cells were allowed to di¡erentiate in 2.5% horse serum
containing DMEM for 2 days [20,21].
2.4. Measurement of mRNA levels
Cells were washed three times with phosphate bu¡ered saline (PBS,
150 mM NaCl, 16 mM Na2HPO4, 4 mM NaH2PO4, pH 7.2) and total
cellular RNA was isolated according to the manufacturer’s protocol
using the high pure RNA isolation kit (Roche Biochemicals, Laval,
QC, Canada). The quality of the RNA sample was determined by 1%
agarose gel electrophoresis [22] and samples containing undegraded
ribosomal RNAs were used for further analysis. The levels of di¡erent
mRNAs were measured by S1 nuclease protection of the appropriate
antisense oligodeoxynucleotide probe. The oligomer probes used for
the analysis of sTnC, f-troponin T (fTnT), f-troponin I (fTnI), K-Tm
and K-acting mRNAs were d(5P-ATCCGACAGCTCCTCCTCA-
GACTTCCCTTT), d(5P-TCAAAGTGGCTGTCAATGAGGGCT-
TGGAGC), d(5P-CCTTGCTGCTCTTCTGCACCTTCACCTCCA),
d(5P-TCTTTCAGCTGGATCTCCTGAATCTCCATC) and d(5P-TG-
AGGGTGACACCGTCCCCAGAATCCAACA) respectively. Oligo-
mers were 5P end labeled with [Q32P]ATP and T4 polynucleotide ki-
nase. Nuclease protection was performed with 5 Wg of total cellular
RNA and 200 ng of radiolabeled probe using the multi-NPA kit
(Ambion, Austin, TX, USA) according to the manufacturer’s proto-
col. The S1 nuclease protected probe product was analyzed by 8 M
urea^20% polyacrylamide gel electrophoresis (PAGE) followed by
autoradiography. The nuclease protected probe was quanti¢ed by
scanning the autoradiogram using the Bio-Rad scanner.
2.5. Sucrose gradient centrifugation
Approximately 5U106 cells were lysed in 800 Wl of a lysis bu¡er (25
mM Tris^HCl, pH 7.6, 250 mM KCl, 10 mM MgCl2, 0.5% Nonidet
P-40, 200 Wg/ml heparin, 50 Wg/ml cycloheximide) and centrifuged at
12 000Ug for 10 min. The 12 000Ug supernatant fraction was centri-
fuged in a 10 ml 10^50% sucrose gradient containing the lysis bu¡er at
40 000 rpm in a Beckman SW41Ti rotor for 2.5 h [20]. The gradient
was fractionated using a Buchler Auto Densi-Flow IIC apparatus.
Total RNA from each fraction was isolated by using 4 M guanidine
thiocyanate as previously described [23] and precipitated with ethanol
using 5 Wg of yeast tRNA as the carrier.
2.6. Measurement of protein levels
Cellular levels of speci¢c contractile proteins were measured by
immunoblotting. The cells were washed three times with phosphate
bu¡ered saline (PBS, 150 mM NaCl, 16 mM Na2HPO4, 4 mM
NaH2PO4, pH 7.2) and lysed in 200 Wl of a bu¡er containing 25
mM Tris^HCl, pH 6.8, 2% sodium dodecyl sulfate (SDS), 10 mM
dithiothreitol (DTT), 10% glycerol, and 0.01% bromophenol blue.
The cell lysate was subjected to 12.5% SDS^PAGE as described pre-
viously [24] and the separated polypeptides were transferred to a ni-
trocellulose membrane. The levels of di¡erent polypeptides were de-
termined by using appropriate antibodies [8]. The antigen^antibody
complex was visualized by horseradish peroxidase conjugated (POD)
anti-rabbit antibodies using the Lumi-Light Western blotting kit
(Roche, Laval, QC, Canada) according to the manufacturer’s proto-
col.
2.7. Measurement of thin ¢lament associated TnC levels
The presence of TnC polypeptide in the thin ¢lament complex was
measured by immunoprecipitating the troponin complex using the
TnT antibody (Sigma, St. Louis, MO, USA). Cells were lysed in
RIPA bu¡er (50 mM Tris^HCl, 150 mM NaCl, 1% Nonidet P-40,
0.5% sodium deoxycholate) and pre-incubated with an equal packed
volume of protein A-Sepharose beads (Sigma) for 1 h. The precleared
supernatant of the cell lysate obtained after 1 min centrifugation at
12 000Ug was incubated with the TnT antibody for 16 h at 4‡C [25].
Protein antibody complexes were then incubated with an equal packed
volume of protein A-Sepharose beads for 2 h. The beads were then
washed four times in RIPA bu¡er and the bound proteins were eluted
at 95‡C in the sample bu¡er (25 mM Tris^HCl, pH 6.8, 2% SDS, 10
mM DTT, 10% glycerol and 0.01% bromophenol blue) for SDS^
PAGE. The eluted samples were analyzed by 12.5% SDS^PAGE.
The co-precipitation of TnC with TnT was examined by immunoblot-
ting using sTnC antibody as described above.
3. Results
3.1. Misexpression of TnC
To investigate how an imbalance in the stoichiometry of the
thin ¢lament proteins a¡ects the regulation of expression of
the contractile protein genes we have transfected di¡erentiat-
ing cells with a construct containing the CMV promoter-driv-
en mouse sTnC cDNA. Transfection e⁄ciency of myotubes
was poor, therefore, we have transfected the myoblasts imme-
diately after they were transferred to the di¡erentiation me-
dium. Co-transfection of these cells with L-galactosidase ex-
pression vector CMV-SPORT-L-gal (Invitrogen) showed that
approximately 30% of cells were transfected. The level of
mRNAs for sTnC, K-actin, fTnT, fTnI and K-Tm in myo-
blasts, myotubes and mock-transfected cells were measured
by S1 nuclease protection analyses. The results show that
the level of sTnC mRNA in transfected cells was approxi-
mately four-fold higher than that in the mock-transfected cells
(Fig. 1). The levels of mRNAs for other thin ¢lament pro-
teins, K-actin, K-Tm, fTnI and fTnT were not in£uenced by
the increased level of sTnC mRNA in transfected cells. The
mock-transfected cells and the cells transfected with the sTnC
cDNA construct both showed comparable levels of K-actin, K-
Tm, fTnI and fTnT mRNAs. None of these mRNAs includ-
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ing the sTnC were present in signi¢cant amounts in the pro-
liferating myoblasts (Fig. 1).
To further examine whether overexpression of the sTnC
mRNA resulted in over-production of the corresponding
polypeptide, the level of sTnC polypeptide was measured by
immunoblotting. Results show that the sTnC level in trans-
fected cells was only approximately 1.5-fold higher than that
in the mock-transfected cells (Fig. 2). Analyses of the K-actin,
fTnT, fTnI and K-Tm levels showed no di¡erence in their
levels between transfected and mock-transfected cells (Fig.
2). Very little or no detectable levels of the thin ¢lament pro-
teins were found in proliferating myoblasts (Fig. 2, Mb).
These results therefore suggest that a nearly four-fold over-
expression of sTnC mRNA did not result in a proportional
increase in the sTnC polypeptide level.
3.2. Translation of sTnC mRNA
To test whether the sTnC mRNA was poorly translated in
the transfected cells, we examined the distribution of cytoplas-
mic sTnC mRNA in a sucrose gradient. Analysis of the ab-
sorption pro¢le of a representative gradient at 260 nm showed
that fractions 3^5 contain ribosomal subunits and monosomes
while fractions 6^12 contain polyribosomes. Results of sTnC
mRNA distribution in the sucrose gradient show that most of
Fig. 1. Levels of di¡erent mRNAs coding for the thin ¢lament pro-
teins. The steady state level of di¡erent mRNAs from myoblast
(Mb), mock-transfected (M) and transfected cells (T) was measured
by S1 nuclease protection of oligodeoxynucleotide probes as de-
scribed in Section 2. The autoradiograms were quanti¢ed by using a
Bio-Rad gel scanner. The relative levels of mRNAs are shown
under each panel. The positions of di¡erent mRNAs are shown by
an arrow beside each panel.
Fig. 2. Levels of di¡erent polypeptides of the thin ¢lament. The
polypeptide levels of thin ¢lament complements in myoblast (Mb),
mock-transfected (M) and transfected cells (T) were measured by
immunoblotting using appropriate antibodies as described in Section
2. The immunoblots were scanned by using a Bio-Rad gel scanner.
The relative levels of di¡erent polypeptides are shown at the bottom
of each panel. The positions of di¡erent polypeptides are shown by
arrows beside each panel.
Fig. 3. Cytoplasmic distribution of sTnC mRNA. The cells were lysed in a polysome bu¡er and the 12 000Ug supernatant fraction was centri-
fuged in a 12 ml 10^50% sucrose gradient at 40 000 rpm for 2.5 h in a Beckman SW41Ti rotor as described in Section 2. 12 fractions were col-
lected and RNA from each fraction was isolated for analysis of sTnC mRNA level by S1 nuclease protection of the probe as described in Sec-
tion 2. A: Mock-transfected myotubes after 3 days of treatment without plasmid DNA. B: Myotubes after 3 days of transfection.
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the sTnC mRNA in both mock-transfected (Fig. 3A) and
transfected cells (Fig. 3B) was present in the translated poly-
ribosomal fractions (fractions 6^12). However, the translated
sTnC mRNA of transfected cells showed a bimodal distribu-
tion (Fig. 3B). This was probably due to a di¡erence in size
between the endogenous and the ectopic sTnC mRNAs since
short vector derived sequences were present at both 3P and 5P
untranslated regions of the ectopic mRNA. Approximately
15% of the total cytoplasmic population of the sTnC
mRNA in both mock-transfected and transfected cells was
present in the non-translated region of the gradient (fractions
1^5). Therefore, no di¡erence in the translation of sTnC
mRNA between the transfected and mock-transfected cells
was found. The relatively poor (1.5-fold) overexpression of
the sTnC polypeptide in spite of the nearly four-fold increase
in the sTnC mRNA level in cells transfected with the sTnC
expression vector was not due to translational repression of
the sTnC mRNA.
3.3. Stability of sTnC
Since the results of our studies discussed above showed that
the level of sTnC was less than what was expected for the
overexpressed translationally active sTnC mRNA, we exam-
ined the possibility of a decrease in the stability of the sTnC
polypeptide in transfected cells. For these studies we ¢rst ex-
amined the distribution of sTnC between the troponin com-
plex and free cytoplasmic states. The troponin C was co-im-
munoprecipitated with an antibody to another polypeptide
partner, the TnT, of the troponin complex of the thin ¢la-
ment. The complex bound to protein A-Sepharose and the
unbound fraction were both analyzed by immunoblotting
for the presence of sTnC. The results (Fig. 4) show that nearly
all of the sTnC was complexed with TnT (Fig. 4A) in mock-
transfected cells. However, in the transfected cells, approxi-
mately the same amount as that of the mock-transfected cells
was present as troponin complex. But nearly 50% of the sTnC
was not present as the troponin complex of the thin ¢lament
(Fig. 4B). No detectable level of sTnC was found in the my-
oblasts (Fig. 4, Mb).
Since the excess sTnC was not present in the thin ¢lament
complex in the transfected cells, we then examined the stabil-
ity of sTnC in the free and thin ¢lament bound forms. For
these analyses, cells were treated with cycloheximide to inhibit
protein synthesis and the level of sTnC in the troponin com-
plex and free state was determined by immunoblotting at
di¡erent times after the drug treatment as described above.
The results of immunoblotting to determine the sTnC levels
are shown in Fig. 5. The results show that the thin ¢lament
bound sTnC was degraded with a half life of approximately
6 h in both mock-transfected and transfected cells. The non-
stoichiometric excess sTnC was present mostly in the cytoplas-
mic free form (Figs. 4 and 5) and was more rapidly degraded
than the thin ¢lament bound form. The half life of free sTnC
of transfected cells was only 3 h. As a control, we have also
examined the stability of K-actin levels in transfected and
mock-transfected cells. During the time course of our studies
the K-actin levels showed no detectable change suggesting that
the K-actin is considerably more stable than the sTnC.
4. Discussion
Most proteins function as multi-subunit complexes consist-
ing of di¡erent polypeptides. These complexes assemble in
precise stoichiometry of its polypeptide partners. To achieve
this, the synthesis of di¡erent polypeptide complements of a
functional protein or a cellular structure is probably tightly
controlled to prevent their misexpression. We have investi-
gated whether check-points exist to control the quantity of
each polypeptide complement of a multi-subunit functional
complex using the thin ¢lament polypeptides of muscle cells
Fig. 4. Analysis of the presence of sTnC in troponin complex. Cell
lysates were prepared in RIPA bu¡er as described in Section 2.
Samples of cell extracts containing equal amounts of protein were
precleared with an equal packed volume of protein A-Sepharose
(Sigma) for 1 h. The precleared cell extract was incubated with TnT
antibody (Sigma) for 16 h at 4‡C [9]. The antigen^antibody complex
was then further incubated with an equal packed volume of protein
A-Sepharose for 3 h at 4‡C. The Sepharose beads were washed in
RIPA bu¡er and the bound proteins were eluted with an SDS con-
taining bu¡er. The eluted polypeptides were separated by PAGE.
The protein A-Sepharose unbound fractions were also separated by
PAGE. The presence of sTnC in both eluted and unbound fractions
was analyzed by Western blotting using sTnC antibody (Research
Genetics) as described in Section 2. Protein A-Sepharose bound (A)
and unbound (B) fractions; M, mock-transfected cells ; Mb, prolifer-
ating myoblasts; T, transfected cells.
Fig. 5. Stability of polypeptides. Cells were treated with 50 Wg/ml
cycloheximide for di¡erent times and the level of thin ¢lament
bound and soluble sTnC was analyzed as described in the legend to
Fig. 4. As control the level of K-actin was also analyzed in the total
cell extract. The immunoblots were performed with sTnC (A^C)
and K-actin antibody (D). The intensities of sTnC and K-actin
bands in these blots were determined by scanning using a Bio-Rad
scanner and were shown at the bottom of each panel. A: Soluble
sTnC in transfected cells. B: Thin ¢lament associated sTnC in trans-
fected cells. C: Thin ¢lament associated sTnC in mock-transfected
cells. D: K-actin in the total cell extract of transfected cells.
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as a model system. In this study we have shown that three- to
four-fold overexpression of sTnC mRNA in mouse C2 myo-
tubes did not result in a corresponding increase of the sTnC
polypeptide level. The sTnC polypeptide level was increased
by only 1.5-fold. We have shown that although the excess
sTnC mRNA was e⁄ciently translated, the translation prod-
uct failed to accumulate in large quantities. A check-point to
control sTnC polypeptide level was detected in myotubes.
Accumulation of large quantities of unassembled sTnC in
the cytoplasm was prevented by preferential rapid degrada-
tion of the soluble form of the sTnC polypeptide. The sTnC
complexed with the thin ¢lament proteins, in both normal
cells and in cells overexpressing sTnC mRNA, were degraded
at a rate slower than that of the free sTnC polypeptide. We
also investigated whether over-production of sTnC may in-
crease the level of other thin ¢lament polypeptides to maintain
the stoichiometry. Results of our studies suggest there was no
detectable di¡erence in the cellular level of several thin ¢la-
ment polypeptides like TnT, TnI, K-Tm and K-actin. There-
fore, accelerated degradation of any excess unassembled TnC
polypeptide appears to be the principle mechanism for main-
taining the quantity of sTnC polypeptide so that each poly-
peptide partner of the thin ¢lament exists in the cell in proper
stoichiometry.
In earlier studies we used a di¡erent approach for misex-
pression of sTnC in C2 myotubes [6^8]. The synthesis of sTnC
polypeptide was blocked by using an antisense oligodeoxynu-
cleotide. In these studies we also detected that control at the
level of polypeptide stability played an important role to
maintain the thin ¢lament composition. Short-term inhibition
of sTnC synthesis resulted in increased stability of this poly-
peptide [8]. Therefore, under circumstances of both under-
production and over-production of the sTnC polypeptide
the check-point works by modulating its rate of degradation.
The mechanism to control this step is not known. It is possi-
ble that conformational changes in sTnC during its assembly
into the thin ¢lament might prevent the formation of the
proteasome complex for degradation [25]. It is also not known
whether misexpression of other polypeptide partners of the
troponin complex will also be regulated by controlling their
turn-over rates.
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